COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cocrystal Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.95−0.07 (-7.20%)
Close on Oct 19, 2026
- Market cap
- $13.05M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -55.5% | -24.7% | -111.4% | |
| Return on assets | -42.9% | -23.3% | -76.2% | |
| Current ratio | 2.68 | 25.05 | 3.68 | |
| Interest coverage | – | -1198.3× | 67.3× | |
| Capex to revenue | – | 11.9% | – | |
| Diluted shares | 2M | 5M | 11M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cocrystal Pharma generated $73.50M from operations and spent $264.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$73.50M
Used
$264.00K
Capital expenditure$264.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-479.0%
×Asset turnover0.05×
×Equity multiplier1.06×
=Return on equity, FY2020-24.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2020 | -479.0% | 0.05× | 1.06× | -24.7% |
| FY2019 | -733.8% | 0.14× | 1.05× | -104.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.83M
- Cash generatingOperating cash flow above zero-$8.19M
- Return on assets improvedROA up on the prior year-56.0% → -65.6%
- Earnings backed by cashOperating cash flow above net income-$8.19M vs -$8.83M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.77 → 3.68
- No dilutionShare count did not rise10M → 11M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –